Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06765265

Impact of Atorvastatin Versus Rosuvastatin on 25 Hydroxy Vitamin D Levels in Patients With Acute Coronary Syndrome

there will be 2 groups of patients with acute coronary syndrome. The patients will receive one of the 2 study drugs and impact on raising Vitamin D level will be seen after 6 months

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Acute Coronary Syndromes Acute Coronary Syndrome Cardiovascular Diseases Heart Diseases Myocardial Ischemia Vascular Diseases

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

King Edward Medical University

Lahore, Punjab Province, 54000, Pakistan

Location status: Recruiting

Location contact

AP Endocrinology

CONTACT

[email protected]

+923004683473

About this study

this randomized clinical trial will include 152 patients of acute coronary syndrome with normal Vitamin D levels. they will be randomized to receive either Atorvastatin or Rosuvastatin. After 6 months of therapy, the impact on Vitamin D levels will be checked

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Acute Coronary Syndrome

25 OH-Vitamin D levels between 30-70ng/ml

Exclusion criteria

Hypercalcemia

hypocalcemia

pregnancy

lactation

hypersensitivity to statins

hypothyroidism

Deranged LFTs & RFTs

Use of following within last 3 months (Vitamin D Supplements, lipid lowering drugs, anti-obesity drugs, corticosteroids)

Treatment and study plan

Rosuvastatin 20 mg/day

Drug

Rosuvastatin 20 mg / Day for 24 weeks

Atorvastatin 40 mg

Drug

Atorvastatin 40mg / Day for 24 weeks

Primary outcomes

  1. Serum Vitamin D

    Time frame: 24 weeks

Secondary outcomes

  1. Lipid Profile

    Time frame: 4 weeks & 24 weeks

Study contacts

Contact information is provided by the study sponsor or research team.

Ali Hussnain

CONTACT

[email protected]

+923317641096

Sponsors and collaborators

Lead sponsor

King Edward Medical University

Other

Registry information

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Jan 9, 2025
Registry last updated
Mar 11, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.